Altamira Therapeutics H1 2024 EPS $(2.11) Up From $(21.55) YoY
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics reported a significant improvement in its H1 2024 earnings, with losses per share decreasing from $(21.55) to $(2.11), marking a 90.21% improvement year-over-year.
September 24, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altamira Therapeutics reported a 90.21% improvement in its H1 2024 EPS, reducing losses from $(21.55) to $(2.11) per share year-over-year.
The significant reduction in losses per share indicates improved financial performance, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100